Market revenue in 2024 | USD 37.3 million |
Market revenue in 2030 | USD 78.9 million |
Growth rate | 13.3% (CAGR from 2025 to 2030) |
Largest segment | Exocrine |
Fastest growing segment | Endocrine |
Historical data | 2018 - 2023 |
Base year | 2024 |
Forecast period | 2025 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Exocrine, Endocrine |
Key market players worldwide | Accuray Inc, AstraZeneca PLC ADR, Novartis AG ADR, Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, Ipsen Pharma, Eli Lilly and Co, Siemens Healthineers AG ADR, Elekta AB ADR |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to pancreatic cancer treatment market will help companies and investors design strategic landscapes.
Exocrine was the largest segment with a revenue share of 88.2% in 2024. Horizon Databook has segmented the Thailand pancreatic cancer treatment market based on exocrine, endocrine covering the revenue growth of each sub-segment from 2018 to 2030.
In Thailand, the pancreatic cancer treatment market is expanding, fueled by increased disease awareness, advancements in treatment options, and growing healthcare investments. According to WHO.
In 2023, Thailand recorded approximately 2,000 new cases of pancreatic cancer, prompting pharmaceutical giants to intensify their focus on this market. For instance, AstraZeneca, has seen a 10% increase in patient enrollment for its pancreatic cancer immunotherapy trials in Thailand.
Such as the ongoing Phase III trials for its anti-PD-L1 therapy, which is expected to enhance patient outcomes in advanced stages of the disease. In addition, Novartis AG has been advancing targeted therapies in the Thai market.
supported by clinical studies, which investigates the efficacy of a combination treatment for pancreatic cancer. These trials reflect the increasing role of innovative therapies in the market, driven by Thailand's growing interest in personalized treatment options.
Horizon Databook provides a detailed overview of country-level data and insights on the Thailand pancreatic cancer treatment market , including forecasts for subscribers. This country databook contains high-level insights into Thailand pancreatic cancer treatment market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
No related regions found.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account